Plant ID: NPO5136
Plant Latin Name: Colliguaja salicifolia
Taxonomy Genus: Colliguaja
Taxonomy Family: Euphorbiaceae
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
NPSR1; | |
AXL; KDR; CDK1; FLT3; AURKB; IGF1R; MAP2K1; PIM1; MET; | |
ALOX12; HSD17B10; NOX4; POLB; | |
PTGS2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Q02750 | CHEMBL3587 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 8.333E-09 | 1.650E-05 | AXL, FLT3, IGF1R, KDR, MAP2K1, MET |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 2.473E-07 | 2.071E-04 | ALOX12, AURKB, AXL, CDK1, IGF1R, KDR, PIM1, PTGS2 |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 5.729E-07 | 4.455E-04 | AURKB, FLT3, IGF1R, KDR, PIM1 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 1.206E-06 | 9.059E-04 | AURKB, AXL, CDK1, FLT3, IGF1R, KDR, MAP2K1, MET, PIM1 |
MF | GO:0005488; binding | GO:0020037; heme binding | 4.095E-06 | 1.621E-03 | CYP1B1, CYP2C19, NOX4, PTGS2 |
BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 8.530E-06 | 2.575E-03 | ALOX12, CYP1B1, KDR, PTGS2 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.853E-06 | 2.575E-03 | CYP1B1, CYP2C19, NOX4 |
CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 1.291E-05 | 3.604E-03 | AURKB, CDK1, POLB |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.527E-05 | 4.055E-03 | FLT3, KDR |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.975E-05 | 4.886E-03 | AXL, CDK1, CYP1B1 |
BP | GO:0009987; cellular process | GO:0007569; cell aging | 2.391E-05 | 5.481E-03 | CDK1, MAP2K1, NOX4 |
BP | GO:0008152; metabolic process | GO:0051054; positive regulation of DNA metabolic process | 3.057E-05 | 6.590E-03 | AURKB, CDK1, IGF1R, NOX4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.267E-05 | 6.971E-03 | CYP1B1, CYP2C19 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 3.825E-05 | 7.785E-03 | AXL, CDK1, FLT3 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.097E-06 | 1.885E-04 | MAP2K1, ALOX12, CYP2C19, PTGS2 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 3.733E-06 | 1.885E-04 | MAP2K1, PIM1, CYP1B1, PTGS2, MET |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 9.754E-06 | 2.362E-04 | CYP1B1, PTGS2, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.527E-05 | 2.362E-04 | MAP2K1, FLT3, PTGS2, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.451E-05 | 2.362E-04 | MAP2K1, FLT3, PIM1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 1.781E-05 | 2.362E-04 | MAP2K1, KDR, PTGS2 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.211E-05 | 2.362E-04 | MAP2K1, KDR, MET, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.870E-05 | 2.362E-04 | ALOX12, CYP2C19, PTGS2 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 2.169E-05 | 2.362E-04 | MAP2K1, KDR, MET, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 2.573E-05 | 2.362E-04 | MAP2K1, KDR, MET, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 3.425E-05 | 2.661E-04 | MAP2K1, KDR, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.363E-05 | 2.362E-04 | MAP2K1, FLT3, MET |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.813E-05 | 2.368E-04 | MAP2K1, MET, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 7.380E-05 | 4.969E-04 | MAP2K1, CDK1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.658E-04 | 9.850E-04 | MAP2K1, KDR, MET, IGF1R |
09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 1.449E-04 | 9.149E-04 | MAP2K1, CDK1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.334E-05 | 3.126E-04 | CYP1B1, CYP2C19, PTGS2 |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 4.443E-04 | 2.493E-03 | FLT3, MET, IGF1R |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 1.276E-03 | 6.204E-03 | KDR, MET, IGF1R |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 1.363E-03 | 6.204E-03 | FLT3, KDR, MET |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.371E-03 | 6.204E-03 | MAP2K1, IGF1R |
09150 Organismal Systems | 09156 Nervous system | hsa04730 | Long-term depression | 1.169E-03 | 6.204E-03 | MAP2K1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.413E-03 | 6.204E-03 | MAP2K1, MET |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 2.550E-03 | 9.905E-03 | MAP2K1, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.772E-03 | 7.457E-03 | MET, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 2.494E-03 | 9.905E-03 | MAP2K1, CDK1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; PTGS2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
NA: NA | Rheumatold arthritis | NA | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; FLT3; PTGS2; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
NA: NA | Joint and muscular pain | NA | PTGS2; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; PTGS2; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; PTGS2; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |